Abstract：
OBJECTIVE: ABO blood group mismatch between the donor and the recipient can affect the success of the transplant as well as problems with the red blood cells during allogeneic haematopoietic cell transplantation (HCT). However, the impact of the Rhesus (Rh) D mismatch on transplant outcomes in allogeneic HCT has been poorly elucidated.
METHODS: We retrospectively evaluated the impact of the RhD mismatch on post-transplant outcomes in 64,923 patients who underwent allogeneic HCT between 2000 and 2021 using a Japanese registry database.
RESULTS: Out of the whole group, 64,293, 322, 270 and 38 HCTs were done when the recipient or donor was RhD-mismatched with (+/+), (-/+), (+/-) or (-/-) combinations. The difference in RhD between recipient/donor (-/+), (+/-) and (-/-) did not affect haematopoietic recovery, acute and chronic graft-versus-host disease (GVHD), overall survival (OS), non-relapse mortality (NRM) or relapse when RhD (+/+) was used as the reference group in multivariate analysis.
CONCLUSIONS: Our registry-based study demonstrated that RhD mismatch between recipient and donor did not significantly impact haematopoietic recovery, GVHD, OS, NRM or relapse after allogeneic HCT. These data suggest that RhD mismatches may not need to be avoided for recipient and donor combinations in allogeneic HCT.
METHODS: We retrospectively evaluated the impact of the RhD mismatch on post-transplant outcomes in 64,923 patients who underwent allogeneic HCT between 2000 and 2021 using a Japanese registry database.
RESULTS: Out of the whole group, 64,293, 322, 270 and 38 HCTs were done when the recipient or donor was RhD-mismatched with (+/+), (-/+), (+/-) or (-/-) combinations. The difference in RhD between recipient/donor (-/+), (+/-) and (-/-) did not affect haematopoietic recovery, acute and chronic graft-versus-host disease (GVHD), overall survival (OS), non-relapse mortality (NRM) or relapse when RhD (+/+) was used as the reference group in multivariate analysis.
CONCLUSIONS: Our registry-based study demonstrated that RhD mismatch between recipient and donor did not significantly impact haematopoietic recovery, GVHD, OS, NRM or relapse after allogeneic HCT. These data suggest that RhD mismatches may not need to be avoided for recipient and donor combinations in allogeneic HCT.
摘要：
目的：供者和受者之间的ABO血型不匹配会影响移植的成功以及异基因造血细胞移植（HCT）过程中的红细胞问题。然而,恒河猴(Rh)D错配对同种异体HCT移植结局的影响尚不清楚.
方法：我们使用日本注册数据库回顾性评估了2000年至2021年间接受同种异体HCT的64,923例患者中RhD错配对移植后结局的影响。
结果：在整个小组中，当受体或供体与(+/+)RhD不匹配时，进行了64,293、322、270和38个HCTs，(-/+),(+/-)或(-/-)组合。接受者/捐赠者之间的RhD差异(-/+)，（+/-）和（-/-）不影响造血恢复，急性和慢性移植物抗宿主病（GVHD），总生存期（OS），在多变量分析中,将RhD(+/+)用作参照组时,非复发死亡率(NRM)或复发.
结论：我们基于注册的研究表明，受体和供体之间的RhD不匹配并没有显著影响造血恢复，GVHD,操作系统,同种异体HCT后NRM或复发。这些数据表明，对于同种异体HCT中的受体和供体组合，可能不需要避免RhD错配。
方法：我们使用日本注册数据库回顾性评估了2000年至2021年间接受同种异体HCT的64,923例患者中RhD错配对移植后结局的影响。
结果：在整个小组中，当受体或供体与(+/+)RhD不匹配时，进行了64,293、322、270和38个HCTs，(-/+),(+/-)或(-/-)组合。接受者/捐赠者之间的RhD差异(-/+)，（+/-）和（-/-）不影响造血恢复，急性和慢性移植物抗宿主病（GVHD），总生存期（OS），在多变量分析中,将RhD(+/+)用作参照组时,非复发死亡率(NRM)或复发.
结论：我们基于注册的研究表明，受体和供体之间的RhD不匹配并没有显著影响造血恢复，GVHD,操作系统,同种异体HCT后NRM或复发。这些数据表明，对于同种异体HCT中的受体和供体组合，可能不需要避免RhD错配。
